Journal of atherosclerosis and thrombosis最新文献

筛选
英文 中文
Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15. Inclisiran在日本患者中的疗效、安全性和药代动力学:ORION-15 的结果。
IF 4.4 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2024-06-01 Epub Date: 2024-01-14 DOI: 10.5551/jat.64454
Shizuya Yamashita, Arihiro Kiyosue, Pierre Maheux, Jorge Mena-Madrazo, Anastasia Lesogor, Qing Shao, Yuko Tamaki, Hidekazu Nakamura, Mizuki Akahori, Kouji Kajinami
{"title":"Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15.","authors":"Shizuya Yamashita, Arihiro Kiyosue, Pierre Maheux, Jorge Mena-Madrazo, Anastasia Lesogor, Qing Shao, Yuko Tamaki, Hidekazu Nakamura, Mizuki Akahori, Kouji Kajinami","doi":"10.5551/jat.64454","DOIUrl":"10.5551/jat.64454","url":null,"abstract":"<p><strong>Aim: </strong>To evaluate the efficacy, safety, and pharmacokinetics (PK) of inclisiran in Japanese patients with high cardiovascular risk and elevated low-density lipoprotein cholesterol (LDL-C).</p><p><strong>Methods: </strong>ORION-15 was a phase 2, double-blind, placebo-controlled randomized trial. Patients with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH), were randomized to inclisiran sodium 100, 200, or 300 mg, or placebo and dosed subcutaneously on Days 1, 90, and 270. The primary endpoint was the percentage change from baseline to Day 180 to demonstrate the superiority of inclisiran vs. placebo. Patients who consented to the PK substudy had additional study procedures for blood collection and safety assessment.</p><p><strong>Results: </strong>Overall, 312 patients (mean age, 63.6 years; male, 74.4%; baseline LDL-C, 114.0 mg/dL) were randomized. Baseline characteristics were well balanced among the groups. At Day 180, inclisiran at all doses demonstrated significant LDL-C and proprotein convertase subtilisin/kexin type 9 (PCSK9) reductions (p<0.0001 for both), which showed a dose-response relationship. The greatest reductions (LDL-C, 65.3%; PCSK9, 79.2%) were with inclisiran sodium 300 mg. At Day 180, >86% of the patients receiving inclisiran achieved the Japan Atherosclerosis Society 2017 lipid management targets compared to 8.9% for placebo. The mean (SD) plasma half-life for inclisiran was 6.8 (2.0)-7.6 (0.8) h. The incidence of adverse events with inclisiran was similar to that with placebo.</p><p><strong>Conclusion: </strong>Inclisiran sodium 100, 200, and 300 mg demonstrated clinically meaningful and statistically significant LDL-C and PCSK9 reductions at Day 180, which were consistent over 12 months. Inclisiran was effective and well tolerated in Japanese patients with hypercholesterolemia, including HeFH.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11150722/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139465512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022. 日本动脉粥样硬化学会(JAS)《2022 年动脉粥样硬化性心血管疾病预防指南》。
IF 4.4 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2024-06-01 Epub Date: 2023-12-19 DOI: 10.5551/jat.GL2022
Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai, Yoshio Fujioka, Yasushi Ishigaki, Shinji Koba, Hirotoshi Ohmura, Tetsuo Shoji, Koutaro Yokote, Hiroshi Yoshida, Masayuki Yoshida, Juno Deguchi, Kazushige Dobashi, Akira Fujiyoshi, Hirotoshi Hamaguchi, Masumi Hara, Mariko Harada-Shiba, Takumi Hirata, Mami Iida, Yoshiyuki Ikeda, Shun Ishibashi, Hideyuki Kanda, Shinji Kihara, Kazuo Kitagawa, Satoru Kodama, Masahiro Koseki, Yoshiro Maezawa, Daisaku Masuda, Takashi Miida, Yoshihiro Miyamoto, Rimei Nishimura, Koichi Node, Midori Noguchi, Mitsuru Ohishi, Isao Saito, Shojiro Sawada, Hirohito Sone, Minoru Takemoto, Akihiko Wakatsuki, Hidekatsu Yanai
{"title":"Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022.","authors":"Tomonori Okamura, Kazuhisa Tsukamoto, Hidenori Arai, Yoshio Fujioka, Yasushi Ishigaki, Shinji Koba, Hirotoshi Ohmura, Tetsuo Shoji, Koutaro Yokote, Hiroshi Yoshida, Masayuki Yoshida, Juno Deguchi, Kazushige Dobashi, Akira Fujiyoshi, Hirotoshi Hamaguchi, Masumi Hara, Mariko Harada-Shiba, Takumi Hirata, Mami Iida, Yoshiyuki Ikeda, Shun Ishibashi, Hideyuki Kanda, Shinji Kihara, Kazuo Kitagawa, Satoru Kodama, Masahiro Koseki, Yoshiro Maezawa, Daisaku Masuda, Takashi Miida, Yoshihiro Miyamoto, Rimei Nishimura, Koichi Node, Midori Noguchi, Mitsuru Ohishi, Isao Saito, Shojiro Sawada, Hirohito Sone, Minoru Takemoto, Akihiko Wakatsuki, Hidekatsu Yanai","doi":"10.5551/jat.GL2022","DOIUrl":"10.5551/jat.GL2022","url":null,"abstract":"","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11150976/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138829792","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Growth Differentiation Factor-15 and Clinical Outcomes in Lower Extremity Artery Disease. 生长分化因子-15 与下肢动脉疾病的临床预后
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2024-06-01 Epub Date: 2024-01-31 DOI: 10.5551/jat.64515
Taku Shikama, Yoichiro Otaki, Tetsu Watanabe, Harutoshi Tamura, Shigehiko Kato, Satoshi Nishiyama, Hiroki Takahashi, Takanori Arimoto, Masafumi Watanabe
{"title":"Growth Differentiation Factor-15 and Clinical Outcomes in Lower Extremity Artery Disease.","authors":"Taku Shikama, Yoichiro Otaki, Tetsu Watanabe, Harutoshi Tamura, Shigehiko Kato, Satoshi Nishiyama, Hiroki Takahashi, Takanori Arimoto, Masafumi Watanabe","doi":"10.5551/jat.64515","DOIUrl":"10.5551/jat.64515","url":null,"abstract":"<p><strong>Aim: </strong>Lower extremity artery disease (LEAD) is an increasingly common health problem that is associated with high mortality due to thrombotic and bleeding events. Growth differentiation factor-15 (GDF15), a stress-response cytokine belonging to the transforming growth factor-beta superfamily, is associated with cardiovascular disease and its outcomes. The aim of the present study was to examine the effect of serum GDF15 levels on clinical outcomes in patients with LEAD.</p><p><strong>Methods: </strong>We measured serum GDF15 levels in 200 patients with LEAD before their initial endovascular therapy. The primary endpoint was the all-cause mortality rate. The secondary endpoints, on the other hand, were thrombotic and bleeding events, such as cerebral infarction, acute coronary syndrome, acute limb ischemia, and Bleeding Academic Research Consortium types 3 and 5.</p><p><strong>Results: </strong>The serum GDF15 levels increased with advancing Fontaine class. Kaplan-Meier analysis revealed that the high-GDF15 group (≥ 2,275 pg/mL) had higher rates of all-cause deaths and thrombotic and bleeding events than the low-GDF15 group (<2,275 pg/mL). Multivariate Cox proportional-hazards regression analysis revealed that GDF15 was an independent predictor of all-cause mortality and thrombotic and bleeding events after adjusting for confounding risk factors. When the ABC-AF-bleeding score was substituted for GDF15, similar results were obtained.</p><p><strong>Conclusion: </strong>Serum GDF15 levels were associated with all-cause mortality and thrombotic and bleeding events in patients with LEAD. Serum GDF15 is a potentially useful marker of clinical outcomes, specifically for tracking thrombotic and bleeding events in patients with LEAD.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11150723/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bathing-Related Ischemic Stroke: Association between Stroke Subtype and Cerebral Small Vessel Disease. 洗澡导致的缺血性中风:中风亚型与脑小血管病之间的关系
IF 4.4 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2024-06-01 DOI: 10.5551/jat.64933
Takahiro Ishikawa, Takeo Sato, Motohiro Okumura, Tatsushi Kokubu, Junichiro Takahashi, Tomomichi Kitagawa, Maki Tanabe, Hiroki Takatsu, Asako Onda, Teppei Komatsu, Kenichi Sakuta, Kenichiro Sakai, Tadashi Umehara, Hidetaka Mitsumura, Yasuyuki Iguchi
{"title":"Bathing-Related Ischemic Stroke: Association between Stroke Subtype and Cerebral Small Vessel Disease.","authors":"Takahiro Ishikawa, Takeo Sato, Motohiro Okumura, Tatsushi Kokubu, Junichiro Takahashi, Tomomichi Kitagawa, Maki Tanabe, Hiroki Takatsu, Asako Onda, Teppei Komatsu, Kenichi Sakuta, Kenichiro Sakai, Tadashi Umehara, Hidetaka Mitsumura, Yasuyuki Iguchi","doi":"10.5551/jat.64933","DOIUrl":"https://doi.org/10.5551/jat.64933","url":null,"abstract":"<p><strong>Aims: </strong>Bathing-related ischemic stroke (BIS) is sometimes fatal. However, its mechanisms and risk factors remain unclear. We aimed to identify the incidence of stroke subtypes in BIS, and clarify the impact of cerebral small vessel disease (CSVD) on BIS.</p><p><strong>Methods: </strong>Consecutive patients with ischemic stroke between October 2012 and February 2022 were retrospectively screened. The inclusion criteria were: 1) onset-to-door time within 7 days; and 2) availability of the results of MRI evaluation of CSVD markers during hospitalization. BIS was defined as an ischemic stroke that occurred while or shortly after bathing. We investigated the incidence of the stroke subtype and the correlation between CSVD markers and BIS.</p><p><strong>Results: </strong>1,753 ischemic stroke patients (1,241 [71%] male, median age 69 years) were included. 57 patients (3%) were included in the BIS group. A higher frequency of large artery atherosclerosis (LAA) (prevalence ratio [PR] 2.069, 95% confidence interval [CI] 1.089 to 3.931, p=0.026) and lower frequency of cardio-embolism (CES) (PR 0.362, 95% CI 0.132 to 0.991, p=0.048) in BIS cases were identified. Moreover, lower periventricular hyperintensity (PVH) Fazekas grade (PR 0.671, 95% CI 0.472 to 0.956, p=0.027) and fewer cerebral microbleeds (CMBs) in deep brain region (PR 0.810, 95%CI 0.657 to 0.999, p=0.049) were associated with BIS cases.</p><p><strong>Conclusions: </strong>The BIS group was more likely to develop LAA and less likely to develop CES. Lower PVH grade and fewer CMBs in deep brain region were associated with the development of BIS.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141199466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cilostazol plus Aspirin vs. Clopidogrel plus Aspirin in Acute Minor Stroke or Transient Ischemic Attack. 西洛他唑加阿司匹林与氯吡格雷加阿司匹林治疗急性轻微中风或短暂性脑缺血发作。
IF 4.4 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2024-06-01 Epub Date: 2023-12-14 DOI: 10.5551/jat.64502
Hsin-Yi Huang, Jia-Hung Chen, Nai-Fang Chi, You-Chia Chen
{"title":"Cilostazol plus Aspirin vs. Clopidogrel plus Aspirin in Acute Minor Stroke or Transient Ischemic Attack.","authors":"Hsin-Yi Huang, Jia-Hung Chen, Nai-Fang Chi, You-Chia Chen","doi":"10.5551/jat.64502","DOIUrl":"10.5551/jat.64502","url":null,"abstract":"<p><strong>Aim: </strong>This study compared the effectiveness, safety, and mortality risks between cilostazol plus aspirin and clopidogrel plus aspirin treatment for patients with acute minor ischemic stroke or transient ischemic attack (TIA).</p><p><strong>Methods: </strong>This retrospective cohort study employed a new-user design and utilized data from the nationwide Health and Welfare Database in Taiwan. Patients were included if they were discharged with newly initiated cilostazol plus aspirin or clopidogrel plus aspirin after primary acute minor ischemic stroke or TIA hospitalization between 2009 and 2018. Inverse probability of treatment weighting was applied to balance covariats between study groups. Effectiveness outcomes were the risks of acute ischemic stroke, acute myocardial infarction (AMI), TIA, and composite cardiovascular events; Safety outcomes were the risks of intracranial hemorrhage (ICH), gastrointestinal bleeding, and composite bleeding events; Mortality outcomes were the risks of fatal stroke, cardiovascular mortality, and all-cause mortality.</p><p><strong>Results: </strong>A total of 3,403 patients were included, of which 578 were treated with cilostazol plus aspirin and 2,825 were treated with clopidogrel plus aspirin. Cilostazol plus aspirin was associated with a higher risk of ICH (HR: 1.82; 95% CI: 1.16-2.84) compared to clopidogrel plus aspirin. No significant differences in the risks of effectiveness or mortality outcomes between the two groups were found.</p><p><strong>Conclusions: </strong>The effectiveness and mortality of the two groups were similar for patients with acute minor ischemic stroke or TIA. However, cilostazol plus aspirin was associated with a higher risk of ICH compared to clopidogrel plus aspirin. Patients treated with cilostazol plus aspirin among this population should be monitored carefully to ensure their safety.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11150718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138796291","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of the Xanthine Oxidase Inhibitor, Febuxostat, on WBC Count in Asymptomatic Hyperuricemia: Subanalysis of the Randomized PRIZE Study. 黄嘌呤氧化酶抑制剂非布索坦对无症状高尿酸血症患者白细胞计数的影响:随机 PRIZE 研究的子分析。
IF 3 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2024-06-01 Epub Date: 2024-01-13 DOI: 10.5551/jat.64574
Mitsuhide Takeshita, Atsushi Tanaka, Hisako Yoshida, Ikuko Nakamura, Yoshisato Shibata, Shiro Hata, Akifumi Kushiyama, Masaaki Okutsu, Tomoko Ishizu, Koichi Node
{"title":"Effect of the Xanthine Oxidase Inhibitor, Febuxostat, on WBC Count in Asymptomatic Hyperuricemia: Subanalysis of the Randomized PRIZE Study.","authors":"Mitsuhide Takeshita, Atsushi Tanaka, Hisako Yoshida, Ikuko Nakamura, Yoshisato Shibata, Shiro Hata, Akifumi Kushiyama, Masaaki Okutsu, Tomoko Ishizu, Koichi Node","doi":"10.5551/jat.64574","DOIUrl":"10.5551/jat.64574","url":null,"abstract":"<p><strong>Aims: </strong>The anti-inflammatory effects of the xanthine oxidase inhibitor, febuxostat, a urate-lowering agent, have been reported in animal studies. However, the anti-inflammatory effects of urate-lowering therapy and its associated cardiovascular protective effects have not been fully determined in actual clinical practice. This study aimed to investigate the effect of febuxostat on white blood cell (WBC) count in patients with asymptomatic hyperuricemia and to assess for potential correlations between changes in WBC count and inflammatory biomarkers and atherosclerosis in this patient population.</p><p><strong>Methods: </strong>This was a post hoc subanalysis of the PRIZE study, a multicenter, prospective, randomized, open-label clinical trial. In the PRIZE study, asymptomatic hyperuricemia patients were randomized to febuxostat group or control group with non-pharmacological therapy and evaluated the effect on vascular. The primary endpoints of this study were the assessment of the time course of WBC count over 24 months and its changes from baseline. Correlations of WBC count with high-sensitivity C-reactive protein (hs-CRP) and mean common carotid artery (CCA)-IMT were also exploratorily examined in the febuxostat group.</p><p><strong>Results: </strong>A total of 444 patients (febuxostat group, n=223; control group, n=221) with WBC measurements available at baseline and at least one of the follow-up time points of 12 or 24 months, were enrolled. Febuxostat modestly, but significantly, reduced WBC counts at 12 and 24 months compared with the baseline levels (P=0.002 and P=0.026, respectively). Notably, the WBC count in the febuxostat group at 12 and 24 months was significantly lower than that in the control group (P=0.007 and P=0.023, respectively). The changes in WBC count were associated with those of hs-CRP (P=0.038), but not with CCA-IMT (P=0.727).</p><p><strong>Conclusions: </strong>Febuxostat therapy for 24 months modestly, but significantly, decreased WBC count in patients with asymptomatic hyperuricemia. This might potentially reflect a modest anti-inflammatory action of febuxostat in clinical settings.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11150717/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139466710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of the Japanese Version of High Bleeding Risk Criteria on Clinical Outcomes in Patients with ST-segment Elevation Myocardial Infarction. 日文版高出血风险标准对 ST 段抬高型心肌梗死患者临床疗效的影响。
IF 4.4 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2024-06-01 Epub Date: 2023-12-14 DOI: 10.5551/jat.64445
Satoshi Konoma, Kenichi Sakakura, Hiroyuki Jinnouchi, Yousuke Taniguchi, Takunori Tsukui, Masashi Hatori, Yusuke Tamanaha, Taku Kasahara, Yusuke Watanabe, Kei Yamamoto, Masaru Seguchi, Hideo Fujita
{"title":"Impact of the Japanese Version of High Bleeding Risk Criteria on Clinical Outcomes in Patients with ST-segment Elevation Myocardial Infarction.","authors":"Satoshi Konoma, Kenichi Sakakura, Hiroyuki Jinnouchi, Yousuke Taniguchi, Takunori Tsukui, Masashi Hatori, Yusuke Tamanaha, Taku Kasahara, Yusuke Watanabe, Kei Yamamoto, Masaru Seguchi, Hideo Fujita","doi":"10.5551/jat.64445","DOIUrl":"10.5551/jat.64445","url":null,"abstract":"<p><strong>Aims: </strong>Bleeding complications are often observed in patients with ST-segment elevation myocardial infarction (STEMI). Although the Japanese version of the high bleeding risk criteria (J-HBR) were established, it has not been sufficiently validated in patients with STEMI. This retrospective study aims to examine whether J-HBR is associated with cardiovascular and bleeding events in patients with STEMI.</p><p><strong>Methods: </strong>We included 897 patients with STEMI and divided them into the J-HBR group (n=567) and the non-J-HBR group (n=330). The primary endpoint was the major adverse cardiovascular events (MACE), defined as the composite of all-cause death, non-fatal myocardial infarction, ischemic stroke, and systemic embolism. Another primary endpoint was total bleeding events defined as type 3 or 5 bleeding events as defined by the Bleeding Academic Research Consortium .</p><p><strong>Results: </strong>During the median follow-up duration of 573 days, 187 MACE and 141 total bleeding events were observed. The Kaplan-Meier curves showed that MACE and total bleeding events were more frequently observed in the J-HBR group than in the non-J-HBR group (p<0.001). Multivariate Cox hazard analysis revealed that after controlling for multiple confounding factors, the J-HBR group was significantly associated with MACE (hazard ratio [HR] 4.676, 95% confidence interval (CI) 2.936-7.448, p<0.001) and total bleeding events (HR 6.325, 95% CI 3.376-11.851, p<0.001).</p><p><strong>Conclusions: </strong>J-HBR is significantly associated with MACE and total bleeding events in patients with STEMI. This study validated J-HBR as a risk marker for bleeding events and suggests J-HBR as a potential risk marker for MACE in patients with STEMI.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11150728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138796294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Physicians' Perspective Toward Hypertensive Disorders of Pregnancy and Future Cardiovascular Diseases in Japan. 日本医生对妊娠期高血压疾病和未来心血管疾病的看法。
IF 4.4 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2024-06-01 Epub Date: 2024-02-01 DOI: 10.5551/jat.64453
Makiko Egawa, Masami Ikeda, Naoyuki Miyasaka, Mariko Harada-Shiba, Masayuki Yoshida
{"title":"Physicians' Perspective Toward Hypertensive Disorders of Pregnancy and Future Cardiovascular Diseases in Japan.","authors":"Makiko Egawa, Masami Ikeda, Naoyuki Miyasaka, Mariko Harada-Shiba, Masayuki Yoshida","doi":"10.5551/jat.64453","DOIUrl":"10.5551/jat.64453","url":null,"abstract":"<p><strong>Aim: </strong>Hypertensive disorders of pregnancy (HDP) are among the obstetric complications reportedly associated with later-life cardiovascular disease (CVD). This study examined physicians' recognition of reproductive history by elucidating their attitude and knowledge.</p><p><strong>Methods: </strong>This study included council members of the Japan Atherosclerosis Society. An Internet-based survey was conducted between August 9 and September 9, 2022.</p><p><strong>Results: </strong>A total of 137 council members completed the questionnaire (response rate: 36%). In terms of the internal medicine subspeciality of the participants, endocrinology was the most common (46%), followed by cardiology (38%). About 70% of the participants considered reproductive history to be important and obtained more information than those who considered it otherwise. In the questionnaire for knowledge about HDP and future diseases, physicians correctly answered 6.8 of 9 questions. Endocrinologists were more likely to ask regarding reproductive history at the initial visit than cardiologists (82.5% vs. 61.5%; p=0.012) and obtained more information from women below 50 years old. Contrarily, cardiologists obtained information on reproductive history from older women (those approaching menopause and those in their 60s and 70s).</p><p><strong>Conclusion: </strong>We found that physicians had a high level of knowledge about HDP and the importance of reproductive information. However, the manner of obtaining information, including the target population, differed depending on the subspeciality. In the future, effective interventions for women with a history of HDP need to be developed in order to encourage physicians to obtain reproductive information to prevent CVD.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11150725/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139722717","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Validation of Estimated Small Dense Low-Density Lipoprotein Cholesterol Concentration in a Japanese General Population. 日本普通人群中估算的小密度低密度脂蛋白胆固醇浓度的验证。
IF 4.4 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2024-06-01 Epub Date: 2023-12-29 DOI: 10.5551/jat.64578
Keisuke Endo, Ryo Kobayashi, Makito Tanaka, Marenao Tanaka, Yukinori Akiyama, Tatsuya Sato, Itaru Hosaka, Kei Nakata, Masayuki Koyama, Hirofumi Ohnishi, Satoshi Takahashi, Masato Furuhashi
{"title":"Validation of Estimated Small Dense Low-Density Lipoprotein Cholesterol Concentration in a Japanese General Population.","authors":"Keisuke Endo, Ryo Kobayashi, Makito Tanaka, Marenao Tanaka, Yukinori Akiyama, Tatsuya Sato, Itaru Hosaka, Kei Nakata, Masayuki Koyama, Hirofumi Ohnishi, Satoshi Takahashi, Masato Furuhashi","doi":"10.5551/jat.64578","DOIUrl":"10.5551/jat.64578","url":null,"abstract":"<p><strong>Aim: </strong>A high level of directly measured small dense low-density lipoprotein cholesterol (sdLDL-C) is a strong risk factor for atherosclerotic cardiovascular disease. A method for estimating sdLDL-C by using Sampson's equation that includes levels of total cholesterol, high-density lipoprotein cholesterol (HDL-C), non-HDL-C and triglycerides (TG) has recently been proposed. We investigated the validation and exploration of estimated sdLDL-C level.</p><p><strong>Methods: </strong>The associations between measured and estimated sdLDL-C levels were investigated in 605 Japanese subjects (men/women: 280/325; mean age: 65±15 years) who received annual health check-ups in the Tanno-Sobetsu Study, a population-based cohort.</p><p><strong>Results: </strong>Estimated sdLDL-C level was highly correlated with measured sdLDL-C level in all subjects (R<sup>2</sup>=0.701), nondiabetic subjects without any medication (n=254, R<sup>2</sup>=0.686) and subjects with diabetes mellitus (n=128, R<sup>2</sup>=0.721). Multivariable regression analysis showed that levels of non-HDL-C, TG and γ-glutamyl transpeptidase (γGTP) were independent predictors of measured sdLDL-C level. In a stratification of the LDL window, all of the subjects with a combination of high non-HDL-C (≥ 170 mg/dL) and high TG (≥ 150 mg/dL) had high levels of measured and estimated sdLDL-C (≥ 35 mg/dL). Furthermore, machine learning-based estimation of sdLDL-C level by artificial intelligence software, Prediction One, was substantially improved by using components of Sampson's equation (R<sup>2</sup>=0.803) and by using those components with the addition of γGTP and deletion of TC (R<sup>2</sup>=0.929).</p><p><strong>Conclusions: </strong>sdLDL-C level estimated by Sampson's equation can be used instead of measured sdLDL-C level in general practice. By building multiple machine learning models of artificial intelligence, a more accurate and practical estimation of sdLDL-C level might be possible.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11150720/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086964","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relationships of Fat Mass Index and Fat-Free Mass Index with Low-Density Lipoprotein Cholesterol Levels in the Tohoku Medical Megabank Community-Based Cohort Study. 东北医疗大型数据库社区队列研究中脂肪质量指数和无脂肪质量指数与低密度脂蛋白胆固醇水平的关系
IF 4.4 2区 医学
Journal of atherosclerosis and thrombosis Pub Date : 2024-06-01 Epub Date: 2024-02-06 DOI: 10.5551/jat.64535
Masato Takase, Tomohiro Nakamura, Naoki Nakaya, Mana Kogure, Rieko Hatanaka, Kumi Nakaya, Ippei Chiba, Ikumi Kanno, Kotaro Nochioka, Naho Tsuchiya, Takumi Hirata, Taku Obara, Mami Ishikuro, Akira Uruno, Tomoko Kobayashi, Eiichi N Kodama, Yohei Hamanaka, Masatsugu Orui, Soichi Ogishima, Satoshi Nagaie, Nobuo Fuse, Junichi Sugawara, Yoko Izumi, Shinichi Kuriyama, Atsushi Hozawa
{"title":"Relationships of Fat Mass Index and Fat-Free Mass Index with Low-Density Lipoprotein Cholesterol Levels in the Tohoku Medical Megabank Community-Based Cohort Study.","authors":"Masato Takase, Tomohiro Nakamura, Naoki Nakaya, Mana Kogure, Rieko Hatanaka, Kumi Nakaya, Ippei Chiba, Ikumi Kanno, Kotaro Nochioka, Naho Tsuchiya, Takumi Hirata, Taku Obara, Mami Ishikuro, Akira Uruno, Tomoko Kobayashi, Eiichi N Kodama, Yohei Hamanaka, Masatsugu Orui, Soichi Ogishima, Satoshi Nagaie, Nobuo Fuse, Junichi Sugawara, Yoko Izumi, Shinichi Kuriyama, Atsushi Hozawa","doi":"10.5551/jat.64535","DOIUrl":"10.5551/jat.64535","url":null,"abstract":"<p><strong>Aims: </strong>Although fat mass (FM) and fat-free mass (FFM) have an impact on lipid metabolism, the relationship between different body composition phenotypes and lipid profiles is still unclear. By dividing the FM and FFM by the square of the height, respectively, the fat mass index (FMI) and fat-free mass index (FFMI) can be used to determine the variations in body composition. This study aimed to investigate the relationship of combined FMI and FFMI with low-density lipoprotein cholesterol (LDL-C) levels.</p><p><strong>Methods: </strong>This cross-sectional study comprised 5,116 men and 13,630 women without cardiovascular disease and without treatment for hypertension, and diabetes. Following sex-specific quartile classification, FMI and FFMI were combined into 16 groups. Elevated LDL-C levels were defined as LDL-C ≥ 140 mg/dL and/or dyslipidemia treatment. Multivariable logistic regression models were used to examine the relationships between combined FMI and FFMI and elevated LDL-C levels.</p><p><strong>Results: </strong>Overall, elevated LDL-C levels were found in 1,538 (30.1%) men and 5,434 (39.9%) women. In all FFMI subgroups, a higher FMI was associated with elevated LDL-C levels. Conversely, FFMI was inversely associated with elevated LDL-C levels in most FMI subgroups. Furthermore, the groups with the highest FMI and lowest FFMI had higher odds ratios for elevated LDL-C levels than those with the lowest FMI and highest FFMI.</p><p><strong>Conclusions: </strong>Regardless of FFMI, FMI was positively associated with elevated LDL-C levels. Conversely, in the majority of FMI subgroups, FFMI was inversely associated with elevated LDL-C levels.</p>","PeriodicalId":15128,"journal":{"name":"Journal of atherosclerosis and thrombosis","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11150719/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139702539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信